For the Quarter Ending December 2025
North America
• In the USA, the Vitamin B9 Price Index fell by 13.66% quarter-over-quarter, reflecting inventory weakness.
• The average Vitamin B9 price for the quarter was approximately USD 50280.00/MT, reflecting export receipts.
• Exporters softened offers; Vitamin B9 Spot Price remained pressured amid ample supply and cautious buyer behavior.
• Early December logistics stability kept delivery schedules intact, supporting the Vitamin B9 Price Forecast into Q1.
• Stable feedstock and energy rates moderated the Vitamin B9 Production Cost Trend, limiting upward pressure on suppliers.
• Seasonal packaging and promotional buying improved the Vitamin B9 Demand Outlook, prompting measured restocking among major formulators.
• Inventory draws and firm contract volumes gradually strengthened the Vitamin B9 Price Index, supporting modest upstream supplier confidence.
• Producers operated at steady rates with minimal outages, allowing predictable supply flows and balanced short-term market conditions.
Why did the price of Vitamin B9 change in December 2025 in North America?
• Ample imports and steady domestic output increased available supply, pressuring quotations despite routine downstream consumption.
• Inventory drawdowns were limited as formulators relied on existing stocks, reducing urgent spot purchasing thereby.
• Stable freight and energy removed logistical inflation, so adjustments reflected demand dynamics not cost shocks.
APAC
• In China, the Vitamin B9 Price Index fell by 3.18% quarter-over-quarter, weaker early-quarter offtake and destocking effects.
• The average Vitamin B9 price for the quarter was approximately USD 43866.67/MT, reported by quarterly sales datasets.
• Early October destocking pressured the Vitamin B9 Spot Price amid subdued export enquiries and accumulated warehouse inventories.
• Mid-November restocking and specification tightness reversed momentum, lifting the Vitamin B9 Price Index and seller confidence briefly.
• Stable corn-glucose feedstock and steady utilities kept the Vitamin B9 Production Cost Trend relatively muted.
• Exporters observed measured buying; the Vitamin B9 Demand Outlook improved toward festivals and year-end restocking.
• Near-term rallies appear limited; the Vitamin B9 Price Forecast anticipates modest gains supported by restocking.
• Producer utilisation and environmental inspections constrained availability, influencing Vitamin B9 Spot Price and negotiated FOB levels.
Why did the price of Vitamin B9 change in December 2025 in APAC?
• Domestic prenatal programmes and hospital buying lifted demand, tightening spot availability and supporting higher offers.
• Environmental inspections reduced some PABA intermediate output, shortening lead times and increasing pressure on availability.
• Exporters defended FOB offers amid year-end shipping risk, prompting buyers to advance shipments and purchase.
Europe
• In Germany, the Vitamin B9 Price Index fell by 3.20% quarter-over-quarter, reflecting weak import demand.
• The average Vitamin B9 price for the quarter was approximately USD 44539.00/MT, as reported locally.
• Vitamin B9 Spot Price tightened as limited prompt availability encouraged importers to secure short-term cargoes.
• Vitamin B9 Price Forecast indicates firmness next quarter driven by seasonal restocking and steady offtake.
• Vitamin B9 Production Cost Trend stayed stable as feedstock and energy costs exerted minimal pressure.
• Vitamin B9 Demand Outlook remains steady as premix and supplement manufacturers pursue measured year-end restocking.
• Vitamin B9 Price Index strengthened December as import offers firmed and buyers secured forward volumes.
• Distributor inventories remained committed but not excessive, allowing buyers to absorb elevated offers without disruptions.
Why did the price of Vitamin B9 change in December 2025 in Europe?
• Supply increases from domestic and foreign producers diluted urgency, weighing on spot and Price Index.
• Stable feedstock and freight costs constrained production cost pressures, preventing additional upward momentum in markets.
• Seasonal procurement patterns and comfortable downstream inventories encouraged just-in-time buying, tempering aggressive price movements recently.
For the Quarter Ending September 2025
North America
• In USA, the Vitamin B9 Price Index rose by 8% quarter-over-quarter, supported by nutraceutical demand.
• The average Vitamin B9 price for the quarter was approximately USD 58233.33/MT reflecting steady demand.
• Vitamin B9 Spot Price remained supported by balanced inventories and measured restocking from formulators recently.
• Vitamin B9 Price Forecast indicates gradual Q4 gains driven by seasonal procurement and export replenishment.
• Vitamin B9 Production Cost Trend remained soft due to ample feedstock and steady intermediate availability.
• Vitamin B9 Demand Outlook remains steady with prenatal, fortified-food and personal care sectors providing offtake.
• Vitamin B9 Price Index weakened in September as inventories accumulated and exporters competed aggressively internationally.
• Major US producers operated reliably with consistent output, supporting continuous shipments and tempering market volatility.
Why did the price of Vitamin B9 change in September 2025 in North America?
• Inventory overhang across domestic and export channels reduced procurement urgency, pressuring quotations during late September.
• Substitution toward methylfolate in premium prenatal formulations diverted volumes from conventional Vitamin B9, weakening demand.
• Ample feedstock and US production kept input costs stable, allowing exporters to adjust offers downward.
APAC
• In China, the Vitamin B9 Price Index rose by 1.26% quarter-over-quarter, reflecting modest restocking activity.
• The average Vitamin B9 price for the quarter was approximately USD 45906.67/MT, per Qingdao assessments.
• Vitamin B9 Spot Price remained firm this quarter, supported by steady export inquiries and restocking.
• Vitamin B9 Price Forecast suggests upward bias as buyers rebuild seasonal inventories ahead of winter.
• Vitamin B9 Production Cost Trend stayed stable, supported by uninterrupted feedstocks and steady energy tariffs.
• Vitamin B9 Demand Outlook remains steady with pharmaceutical and nutraceutical procurement disciplined, limiting speculative buying.
• Vitamin B9 Price Index declined in September due to downstream destocking and holiday buying pauses.
• Producers trimmed run-rates and idled lines to rebalance stocks, intermittently tightening spot availability for buyers.
Why did the price of Vitamin B9 change in September 2025 in APAC?
• Uninterrupted feedstock and stable energy tariffs contained production costs, limiting upward price pressure in September.
• Downstream destocking and Golden Week pauses reduced export inquiries, weakening September spot pricing in APAC.
• Exporters trimmed offers amid subdued international demand, while selective line idlings aided inventory rebalancing efforts.
Europe
• In Germany, the Vitamin B9 Price Index rose by 1.26% quarter-over-quarter, driven by downstream restocking.
• The average Vitamin B9 price for the quarter was approximately USD 46012.00/MT for German imports.
• Vitamin B9 Spot Price stayed range-bound with weekly declines, reflecting balanced supply-demand and cautious buying.
• Vitamin B9 Price Forecast indicates modest recovery as scheduled procurement resumes, providing limited upward pressure.
• Vitamin B9 Production Cost Trend muted due to ample feedstock availability, restraining upstream cost pressures.
• Vitamin B9 Demand Outlook remains steady with prenatal and nutraceutical procurement predictable, supporting measured buying.
• Inventory accumulation moderated spot bids, while softer export offers weighed on the Vitamin B9 Price Index.
• Export production remained uninterrupted; ports operated smoothly, preserving flows and constraining volatility in Vitamin B9 Spot Price.
Why did the price of Vitamin B9 change in September 2025 in Europe?
• Downstream inventory surplus reduced immediate procurement urgency, causing downward pressure on September import Price Index.
• Export offers softened with origin production intact, translating into lower costs and softer import prices.
• Logistics operated smoothly, enabling on-time deliveries, preventing cost spikes but failing to stimulate urgent buying.
For the Quarter Ending June 2025
North America
• The Vitamin B9 Spot Price in North America climbed steadily throughout Q2 which was supported by heightened Q2 procurement among fortified food and nutraceutical manufacturers.
• The Price Index closed at USD 58,200/MT FOB New Jersey by the end of June that reflected robust market confidence and a tightening spot availability environment.
• In April, a 1% rise was attributed to advanced restocking by formulators aligning their Q2 cycles with forecasted Q3 supplement launches.
• May experienced a 1.89% uptick as manufacturers have reacted to supplier advisories suggesting constrained availability during the early summer.
• June saw a more accelerated 3.9% increase driven by institutional purchases and demand contracts from OTC pharmaceutical producers seeking inventory security.
• The Vitamin B9 Demand Outlook remained strong, particularly in prenatal and general wellness supplements, sustaining purchasing momentum through Q2.
• The Vitamin B9 Production Cost Trend was broadly stable due to consistent input prices and predictable domestic energy and labor costs.
• Buyers across North America maintained structured procurement plans, limiting price volatility by balancing proactive restocking with predictable formulation cycles.
• Why did the price change in July 2025?
Prices softened marginally in July, as Q2 bulk purchases had already secured near-term requirements, leading to a temporary reduction in active restocking activity across pharmaceutical and supplement formulators.
Asia Pacific
• The Vitamin B9 Spot Price in the APAC region remained stable to firm across Q2, underpinned by consistent regional demand and proactive procurement by bulk buyers.
• The Price Index was recorded at USD 46,500/MT FOB Qingdao by June, reflecting well-balanced trading fundamentals and controlled export flows.
• April registered a 5.10% price rise, driven by accelerated restocking from Southeast Asian and South Asian importers preparing for Q3 public health initiatives.
• May and June each observed a 0.22% month-on-month increase, as suppliers maintained export parity pricing and buyers kept order volumes regular.
• The Vitamin B9 Demand Outlook remained firm due to stable consumption by multivitamin premix companies and institutional nutrition programs across Asia and the Middle East.
• The Vitamin B9 Production Cost Trend remained favorable, aided by steady feedstock availability, unimpeded throughput, and high factory utilization rates in China.
• Exporters maintained well-spaced contract delivery schedules, reducing pricing pressures and ensuring a controlled flow into regional ports.
• APAC buyers demonstrated caution in exceeding replenishment targets, contributing to a flattened pricing trajectory by end-Q2.
• Why did the price change in July 2025?
Prices held steady in July as regional buyers delayed new purchases, given sufficient carryover inventories from Q2 and the absence of immediate Q3 demand triggers.
Europe
• The Vitamin B9 Spot Price in Europe moved gradually upward across Q2, with importers responding to localized supply risk and modest global firming.
• The Price Index reached USD 46,620/MT CFR Hamburg by June, signalling a stable yet slightly firm market supported by cautious stockpiling.
• April saw a 5.04% price increase as regional buyers anticipated stronger Q3 food supplement sales and front-loaded procurement accordingly.
• May posted a restrained 0.22% increase, as distributors synchronized local pricing with international offer levels without pushing excess volume.
• Another 0.21% gain in June was recorded as producers finalized end-of-quarter inventory adjustments, avoiding oversupply.
• The Vitamin B9 Demand Outlook remained consistent throughout Q3 which was driven by the fortified breakfast foods, prenatal nutrition and over-the-counter health categories.
• The Vitamin B9 Production Cost Trend remained moderate, supported by manageable intra-EU logistics and stable CIF valuations from origin markets.
• Buyers in Western and Central Europe employed phased inventory strategies to prevent oversupply while maintaining readiness for Q3 consumer demand.
• Why did the price change in July 2025?
Prices flattened or slightly corrected in July as European buyers paused procurement activity to draw down Q2 inventories, with limited urgency for early Q3 acquisitions.
For the Quarter Ending March 2025
North America
The Vitamin B9 market in North America posted a steady price increase in the first quarter of 2025, with average prices rising by around 12.66% compared to the previous quarter. This upward shift started in December due to higher winter demand for folic acid supplements and carried forward into the new year. Limited stock availability from late 2024 created a need for aggressive procurement as the quarter opened.
Buyers not only placed fresh orders to support ongoing production cycles but also moved to build extra inventory to guard against any possible supply delays. Seasonal transition from winter to spring also had an impact on immediate consumption trends and the demand from pharmaceuticals and nutraceuticals sectors remained consistent and healthy.
Meanwhile, food and beverage manufacturers secured stocks based on routine production schedules. Tariff adjustments on certain pharmaceutical components added a layer of uncertainty. This pushed some Vitamin B9 suppliers and distributors to firm up supply agreements early. Overall, the Vitamin B9 market stayed active, with both supplement and pharmaceutical demand contributing to this price rise in the first quarter of 2025.
Asia Pacific
The Asia Pacific Vitamin B9 market witnessed a sharp price increase during the first quarter of 2025, with an average rise of about 45.26% from the previous quarter. The price rally that began in December continued well into March. This increase in Vitamin B9 prices was driven by stock shortages and increased procurement ahead of the Chinese Lunar New Year.
China which is the region’s largest supplier of folic acid experienced a slow production during the holiday period, which tightened availability and raised prices across export markets. Procurement specialists in key APAC countries moved swiftly to secure inventories for immediate and upcoming production cycles. Downstream demand from the pharmaceuticals and nutraceuticals sectors remained firm, whereas the food and beverage manufacturers maintained a need-based procurement approach to sustain routine output.
The seasonal transition from cooler months to spring played a supporting role, as consumption patterns gradually shifted without a dramatic slowdown. The Vitamin B9 market in Asia Pacific remained buoyant throughout the first quarter of 2025, with Vitamin B9 suppliers and distributors reporting sustained orders and firm pricing trends.
Europe
The Vitamin B9 market in Europe registered a noticeable price increase in the first quarter of 2025, averaging a 30.32% rise compared to the concluding quarter of 2024. The surge was largely a result of tightening availability stemming from higher winter consumption and reduced inventory positions as the year began. Buyers moved quickly in January to cover production requirements and rebuild safety stocks which led to increased procurement activity.
Pharmaceuticals and nutraceuticals sectors due to increase in the end-user demand led to higher price trends of Vitamin B9, while food and beverage manufacturers placed requirement-based orders to ensure uninterrupted production. The seasonal shift from colder months to spring brought slight changes in consumption behaviour, but overall downstream demand remained stable.
Additionally, the firmness in prices of Folic Acid from Asia Pacific markets indirectly supported European price movements, as global Vitamin B9 market sentiment leaned positive. By the end of first quarter of 2025, Vitamin B9 suppliers and distributors reported steady enquiries and firm negotiations and was reflected in the sustained market activity throughout the quarter.
